443 related articles for article (PubMed ID: 17240435)
1. Epidermal growth factor receptor signaling enhanced by long-term medroxyprogesterone acetate treatment in endometrial carcinoma.
Zhao S; Chen X; Lu X; Yu Y; Feng Y
Gynecol Oncol; 2007 Apr; 105(1):45-54. PubMed ID: 17240435
[TBL] [Abstract][Full Text] [Related]
2. Overexpressed epidermal growth factor receptor (EGFR)-induced progestin insensitivity in human endometrial carcinoma cells by the EGFR/mitogen-activated protein kinase signaling pathway.
Ai Z; Wang J; Wang Y; Lu L; Tong J; Teng Y
Cancer; 2010 Aug; 116(15):3603-13. PubMed ID: 20564127
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor signaling pathway involved in progestin-resistance of human endometrial carcinoma: In a mouse model.
Xu Y; Tong J; Ai Z; Wang J; Teng Y
J Obstet Gynaecol Res; 2012 Dec; 38(12):1358-66. PubMed ID: 22612393
[TBL] [Abstract][Full Text] [Related]
4. Transforming growth factor gene expression in human endometrial adenocarcinoma cells: regulation by progestins.
Gong Y; Anzai Y; Murphy LC; Ballejo G; Holinka CF; Gurpide E; Murphy LJ
Cancer Res; 1991 Oct; 51(20):5476-81. PubMed ID: 1833051
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms involved in the evolution of progestin resistance in human breast cancer cells.
Murphy LC; Dotzlaw H; Wong MS; Miller T; Murphy LJ
Cancer Res; 1991 Apr; 51(8):2051-7. PubMed ID: 1849041
[TBL] [Abstract][Full Text] [Related]
6. Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia.
Vereide AB; Kaino T; Sager G; Arnes M; Ørbo A
Gynecol Oncol; 2006 May; 101(2):214-23. PubMed ID: 16325240
[TBL] [Abstract][Full Text] [Related]
7. [Influence of long-term treatment with MPA on the biological character of endometrial carcinoma Ishikawa cell].
Zhao SJ; Chen XJ; Feng YJ
Fen Zi Xi Bao Sheng Wu Xue Bao; 2007 Apr; 40(2):103-12. PubMed ID: 17580663
[TBL] [Abstract][Full Text] [Related]
8. Regulation of plasminogen activator inhibitor 1 expression by interaction of epidermal growth factor with progestin during decidualization of human endometrial stromal cells.
Lockwood CJ
Am J Obstet Gynecol; 2001 Apr; 184(5):798-804; discussion 804-5. PubMed ID: 11303186
[TBL] [Abstract][Full Text] [Related]
9. Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate.
Buchanan G; Birrell SN; Peters AA; Bianco-Miotto T; Ramsay K; Cops EJ; Yang M; Harris JM; Simila HA; Moore NL; Bentel JM; Ricciardelli C; Horsfall DJ; Butler LM; Tilley WD
Cancer Res; 2005 Sep; 65(18):8487-96. PubMed ID: 16166329
[TBL] [Abstract][Full Text] [Related]
10. [Effect and regulation of metformin on endometrial carcinoma subline of progestin-resistance].
Niu YJ; Shi HR; Xie Y
Zhonghua Fu Chan Ke Za Zhi; 2016 Feb; 51(2):135-40. PubMed ID: 26917483
[TBL] [Abstract][Full Text] [Related]
11. The expression and action of granulocyte macrophage-colony stimulating factor and its interaction with TGF-beta in endometrial carcinoma.
Ripley D; Tang XM; Ma C; Chegini N
Gynecol Oncol; 2001 May; 81(2):301-9. PubMed ID: 11330966
[TBL] [Abstract][Full Text] [Related]
12. Molecular tools to reestablish progestin control of endometrial cancer cell proliferation.
Dai D; Kumar NS; Wolf DM; Leslie KK
Am J Obstet Gynecol; 2001 Apr; 184(5):790-7. PubMed ID: 11303185
[TBL] [Abstract][Full Text] [Related]
13. Changes in protein tyrosine phosphatase type IVA member 1 and zinc finger protein 36 C3H type-like 1 expression demonstrate altered estrogen and progestin effect in medroxyprogesterone acetate-resistant and estrogen-independent breast cancer cell models.
Pennanen PT; Sarvilinna NS; Purmonen SR; Ylikomi TJ
Steroids; 2009; 74(4-5):404-9. PubMed ID: 19146866
[TBL] [Abstract][Full Text] [Related]
14. Up-regulation of nuclear receptor corepressor (NCoR) in progestin-induced growth suppression of endometrial hyperplasia and carcinoma.
Kashima H; Horiuchi A; Uchikawa J; Miyamoto T; Suzuki A; Ashida T; Konishi I; Shiozawa T
Anticancer Res; 2009 Apr; 29(4):1023-9. PubMed ID: 19414341
[TBL] [Abstract][Full Text] [Related]
15. Progestin treatment decreases CD133+ cancer stem cell populations in endometrial cancer.
Guy MS; Qamar L; Behbakht K; Post MD; Sheeder J; Sartorius CA; Spillman MA
Gynecol Oncol; 2016 Mar; 140(3):518-26. PubMed ID: 26731726
[TBL] [Abstract][Full Text] [Related]
16. Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study.
Singh M; Zaino RJ; Filiaci VJ; Leslie KK
Gynecol Oncol; 2007 Aug; 106(2):325-33. PubMed ID: 17532033
[TBL] [Abstract][Full Text] [Related]
17. Progesterone receptor A and B expression and progestagen treatment in growth and spread of endometrial cancer cells in nude mice.
Hanekamp EE; Kühne LM; Grootegoed JA; Burger CW; Blok LJ
Endocr Relat Cancer; 2004 Dec; 11(4):831-41. PubMed ID: 15613456
[TBL] [Abstract][Full Text] [Related]
18. Dienogest, a novel synthetic steroid, overcomes hormone-dependent cancer in a different manner than progestins.
Katsuki Y; Shibutani Y; Aoki D; Nozawa S
Cancer; 1997 Jan; 79(1):169-76. PubMed ID: 8988742
[TBL] [Abstract][Full Text] [Related]
19. Progestin-induced caveolin-1 expression mediates breast cancer cell proliferation.
Salatino M; Beguelin W; Peters MG; Carnevale R; Proietti CJ; Galigniana MD; Vedoy CG; Schillaci R; Charreau EH; Sogayar MC; Elizalde PV
Oncogene; 2006 Dec; 25(59):7723-39. PubMed ID: 16799639
[TBL] [Abstract][Full Text] [Related]
20. Roles of SIRT1/FoxO1/SREBP-1 in the development of progestin resistance in endometrial cancer.
Wang Y; Zhang L; Che X; Li W; Liu Z; Jiang J
Arch Gynecol Obstet; 2018 Nov; 298(5):961-969. PubMed ID: 30206735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
